Oncodetect White Paper

Download our latest white paper

Explore how the Oncodetect MRD test works. Download our easy-to-understand white paper, "Uncovering the Hidden Traces of Cancer and Empowering More Informed Cancer Decisions" to learn:

  • How the test detects and quantifies ctDNA
  • The analytical and clinical validation process for the test
  • The clinical utility of the test in colorectal cancer
Two folders that say "Oncodetect MRD test: Uncovering the Hidden Traces of Cancer and Empowering Informed Cancer Decisions" sitting on an orange background.
Two folders that say "Oncodetect MRD test: Uncovering the Hidden Traces of Cancer and Empowering Informed Cancer Decisions" sitting on an orange background.

Footnotes

This test was developed, and its performance characteristics determined by Genomic Health, Inc. The Oncodetect test was clinically validated in colorectal cancer patients with stage II-IV disease. Performance characteristics may not apply in tumor types not included in this test’s clinical validation. The test has not been cleared or approved by the US Food and Drug Administration. The test has been validated as a Laboratory Developed Test per institutional and applicable CLIA regulation (CLIA# 03D2048606) and College of American Pathology (CAP# 8869063) as qualified to perform high complexity clinical laboratory testing.